US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% SNDK $1,704.16 ▼-0.92%
FinancialContent

G1 Therapeutics, Inc. - Common Stock (NQ:GTHX)

7.150 UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about G1 Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
From G1 Therapeutics
Via GlobeNewswire
News headline image
G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium
From G1 Therapeutics
Via GlobeNewswire
News headline image
Earnings Preview For G1 Therapeutics ↗
 
Via Benzinga
News headline image
Analyst Ratings for G1 Therapeutics ↗
 
Via Benzinga
News headline image
Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Analyst Ratings for G1 Therapeutics ↗
 
Via Benzinga
News headline image
Where G1 Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
Recap: G1 Therapeutics Q1 Earnings ↗
 
Via Benzinga
News headline image
Earnings Preview: G1 Therapeutics ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights
From G1 Therapeutics
Via GlobeNewswire
News headline image
G1 Therapeutics’ COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO)
From G1 Therapeutics
Via GlobeNewswire
News headline image
Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Multiple Analyses Also Describe Significant Burden of Chemotherapy-Induced Myelosuppression and Impact on Healthcare Resource Utilization in ES-SCLC 
From G1 Therapeutics
Via GlobeNewswire
News headline image
G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium
From G1 Therapeutics
Via GlobeNewswire
News headline image
Why Nokia Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Black Diamond Therapeutics Announces CEO Transition
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023 ↗
 
Via Benzinga
News headline image
G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights
From G1 Therapeutics
Via GlobeNewswire
News headline image
New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
From G1 Therapeutics
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  Friday's session saw 59 companies set new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  On Friday, 54 companies hit new 52-week lows. 
Via Benzinga
News headline image
Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy
From G1 Therapeutics
Via GlobeNewswire
News headline image
New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer
Real-World Data Show No Association Between Patient Characteristics and Risk of Myelosuppressive Events 
From G1 Therapeutics
Via GlobeNewswire
News headline image
New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)
From G1 Therapeutics
Via GlobeNewswire
News headline image
Benzinga Pro's Top 5 Stocks To Watch For Tuesday, May 9, 2023: BABA, TSM, LCID, H, GTHX ↗
Alibaba (BABA) - China's most economically-important companies will be in focus this week ahead of earnings out of the nation's second largest ecommerce company behind Alibaba, JD.com (JD). 
Via Benzinga
News headline image
G1 Therapeutics Provides First Quarter 2023 Financial Results and Operational Highlights
From G1 Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >